Browsing by Author "Schutz, N"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group
    (Taylor and Francis Ltd., 2023) Peña, C; Riva, E; Schutz, N; Ramírez, A; Vásquez, J; del-Carpio, D; Seehaus, C; Ochoa, P; Vengoa, R; Duarte, P; Martínez-Cordero, H; Figueredo, Y; Ríos, RO; Ramírez, J; Bove, V; Roa, M; Russo, M; Espinoza, M; Rodriguez, G; Remaggi, G; Enciso, ME; Chandía, M; Fantl, D.
    Primary plasma cell leukemia (pPCL) is an infrequent and aggressive plasma cell disorder. The prognosis is still very poor, and the optimal treatment remains to be established. A retrospective, multicentric, international observational study was performed. Patients from 9 countries of Latin America (LATAM) with a diagnosis of pPCL between 2012 and 2020 were included. 72 patients were included. Treatment was based on thalidomide in 15%, proteasome inhibitors (PI)-based triplets in 38% and chemotherapy plus IMIDs and/or PI in 29%. The mortality rate at 3 months was 30%. The median overall survival (OS) was 18 months. In the multivariate analysis, frontline PI-based triplets, chemotherapy plus IMIDs and/or PI therapy, and maintenance were independent factors of better OS. In conclusion, the OS of pPCL is still poor in LATAM, with high early mortality. PI triplets, chemotherapy plus IMIDs, and/or PI and maintenance therapy were associated with improved survival. © 2023 Informa UK Limited, trading as Taylor & Francis Group.